Hyris partnered with prestigious academic and research teams to develop rapid T-Cell tests for global clinical use, in order to track patient immunity levels to specific infections. The solution leverages the portability and reliability of the Hyris System™, enabling the deployment of T-cell testing in any setting, at any time, with real-time results immediately available through Hyris dedicated software.
Within this pandemic phase, Hyris keeps offering a wide range of solutions to support medical actors and decision-makers in the fight against Covid-19. Since July 2020, the Hyris System™ has proved to be instrumental in keeping people safe, at a global scale, through the SARS-CoV-2 Human test and SARS-CoV-2 Environmental, operated via a variety of samples, detecting virus presence regardless of the main Variants of Concern.
Alongside limiting the spread of SARS-CoV-2 new variants and potential hotspots, getting high immunity rates among the population is the number one priority for policymakers and health institutions. Hyris integrated its solutions with a simple yet effective test to measure a patient T-cell immune response to the SARS-CoV-2 virus, which causes COVID-19.
The T-Cell clinical test kit has been developed within an exclusive licensing agreement between Hyris and Duke-NUS Medical School. This new kit enables to quickly evaluate T-cell immune responses in COVID-19 inoculated or convalescent patients, as well as measuring individual immunity levels for vaccinated people. This new test marks a new dimension for vaccine strategies as we face the threat of new virus variants.